862119-83-3

Basic information

• Product Name: (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester
• Synonyms: (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester
• CAS NO: 862119-83-3
• Molecular Formula: C13H20N2O4
• Molecular Weight: 268.3089
• Mol File: 862119-83-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 474.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• PKA: 13.06±0.40(Predicted)
• CAS DataBase Reference: (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester(862119-83-3)
• EPA Substance Registry System: (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester(862119-83-3)

Safety Data

• Hazardous Substances Data: 862119-83-3(Hazardous Substances Data)

Usage

Description

(1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester is a complex organic compound characterized by the presence of a cyclopropane ring, a carboxylic acid group, and an ethyl ester. It also features a vinyl group and a pyrrolidine ring, with a substituted amino and hydroxy group. (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester's structural complexity suggests potential applications in pharmaceuticals or materials science, and its properties and reactivity warrant further investigation.

Uses

Used in Pharmaceutical Industry:
(1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester is used as a potential pharmaceutical agent for its unique structural features, which may offer novel therapeutic properties and reactivity in drug development.
Used in Materials Science:
In the field of materials science, (1R,2S)-1-[(2S,4R)-(4-hydroxy-pyrrolidine-2-carbonyl)-amino]-2-vinyl-cyclopropanecarboxylic acid ethyl ester is utilized for its potential to contribute to the development of new materials with specific properties, such as polymers or other synthetic materials, due to its diverse functional groups and structural complexity.

Upstream product

• 862119-82-2 (2S,4R)-tert-butyl 2-((1R,2S)-1-(ethoxycarbonyl)-2-vinylcyclopropylcarbamoyl)-4-hydroxypyrrolidine-1-carboxylate 
• 669008-08-6 (2S,4R)-tert-butyl 2-((trans)-1-(ethoxycarbonyl)-2-vinylcyclopropylcarbamoyl)-4-hydroxypyrrolidine-1-carboxylate 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 259214-54-5 ethyl (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 259214-54-5 ethyl (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 

Downstream Products

• 552335-44-1 (1R,2S)-ethyl 1-((2S,4R)-1-((S)-2-(((tert-butoxy)carbonyl)amino)non-8-enoyl)-4-hydroxypyrrolidine-2-carboxamido)-2-vinylcyclopropanecarboxylate 
• 790305-05-4 tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-hydroxy-5,16-dioxo-1,2,3,5,6,7,8, 9,10,11,13a,14,14a,15,16,16a-hexadecahydronaphthylcyclopropanoyl[e]pyrrolo[1,2-a][1,4]diazacyclopenta decyne-6-yl-carbamate 

Relevant articles and documents

Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease

HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate im

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.